A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the
clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Financial Summary
| Share Statistics | BCTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $29.9 | $208.8 | 13% |
|
| Shares Out (Mil) | 7.3 | 53.9 | 18% |
|
| Institutional Ownership | 78.2% | 93.1% | 47% |
|
| Float (Mil) | 7.9 | 41.4 | 16% |
|
| Beta | 1.53 | 0.95 | 83% |
|
| Avg Daily Volume (000s) | 58 | 614 | 30% |
|
| Price Change (52-week) |
(71.0%) | 45.3% | 12% |
|
| Growth | BCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (45.7%) | (10.2%) | 8% |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($31) | ($44) | 20% |
|
| EPS (TTM) | ($9.657) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($31) | ($33) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $14 | $174 | 9% |
|
| Valuation | BCTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.02 | 2.09 | 26% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BCTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (139.2%) | (47.2%) | 4% |
|
| ROE | (168.2%) | (54.2%) | 5% |
|
| Liabilities to Assets | 13.5% | 29.1% | 8% |
|
| F-Score | 3 | 2 | 18% |
|
BriaCell Therapeutics Corp. did not pass any screens on 10/16/2026.
